HNF-1α Dimerization Domain Bispecific Antibody Avidity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing multispecific binding agents, such as antibodies, often focus on improving specific functional aspects but fail to confer all desired pharmacological significance, and existing bispecific antibodies lack a dimerization component that enhances their functional characteristics.
Innovation Solution
The development of bispecific binding agents comprising two fusion proteins, each with a first scFv that binds a tumor antigen, a second scFv that binds CD3, and a dimerization component based on human hepatocyte nuclear factor-1 alpha (HNF-1α), which includes a sequence at least 90% identical to residues 1-32 of HNF-1α, facilitating homodimerization and improving binding affinity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant DNA technology is used to generate multispecific antibodies, then functional aspects can be improved, but all desired pharmacological significance cannot be achieved
Solution Approach 1:
The antibody is divided into separate functional domains: variable regions (scFv) for antigen binding and a constant region containing the HNF-1α dimerization domain. This segmentation allows each domain to be optimized independently for its specific function while maintaining overall protein stability and pharmacological properties.
Solution Approach 2:
The patent creates a composite protein structure by fusing different antibody components (scFv from different specificities) with a dimerization domain (HNF-1α). This composite structure combines the binding capabilities of different antibodies with the stabilizing and multimerizing properties of the HNF-1α domain, achieving desired pharmacological significance.
2Adaptability or versatility
If engineered antibodies are created with unique formats, then certain functional aspects are improved, but not all desired functional properties are achieved
Solution Approach 1:
The HNF-1α dimerization domain serves multiple functions simultaneously: it mediates homodimerization of the antibody molecules, provides structural stability to the engineered protein, and enables the formation of multispecific binding agents. This multi-functionality increases adaptability without proportionally increasing complexity.
Solution Approach 2:
The HNF-1α dimerization domain acts as an intermediary element that connects and stabilizes the different scFv components. It mediates the interaction between monomeric units to form functional dimers, enabling the antibody to achieve desired functional properties through this intermediate structural element.
3Strength
If dimerization component is added to bispecific binding agent, then avidity and potency are increased, but structural complexity increases
Solution Approach 1:
The patent merges the binding functions of different antibodies with the dimerization function of HNF-1α into a single integrated protein structure. This combining approach increases binding avidity by enabling multivalent interactions while maintaining a relatively simple overall architecture through the use of a single dimerization domain.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inclusion of the HNF-1α dimerization component enhances the functional characteristics of bispecific binding agents, leading to increased avidity and potency in targeting tumor cells, with improved T-cell mediated killing and prolonged serum half-life compared to agents lacking this component.
Implementation Method 1
a dimerization component comprising a human hepatocyte nuclear factor-1 alpha (HNF-1α) element, wherein the HNF-1α element comprises a sequence that is at least 90% identical to residues 1-32 of SEQ ID NO:1 and capable of homodimerization
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present invention provides, among other things, dimeric multispecific binding agents (e.g., fusion proteins comprising antibody components) that have improved properties over multispecific binding agents without the capability of dimerization.